Neurogene, Inc./$NGNE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Neurogene, Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Ticker
$NGNE
Sector
Primary listing
Employees
131
Headquarters
Website
Neurogene, Inc. Metrics
BasicAdvanced
$414m
-
-$4.24
1.89
-
Price and volume
Market cap
$414m
Beta
1.89
52-week high
$37.27
52-week low
$11.77
Average daily volume
170k
Financial strength
Current ratio
16.56
Quick ratio
16.42
Long term debt to equity
2.577
Total debt to equity
3.734
Interest coverage (TTM)
-20,641.60%
Profitability
EBITDA (TTM)
-100.116
Management effectiveness
Return on assets (TTM)
-20.66%
Return on equity (TTM)
-31.41%
Valuation
Price to book
1.55
Price to tangible book (TTM)
1.55
Price to free cash flow (TTM)
-7.207
Free cash flow yield (TTM)
-13.88%
Free cash flow per share (TTM)
-3.674
Growth
Earnings per share change (TTM)
-0.96%
3-year earnings per share growth (CAGR)
-68.83%
Neurogene, Inc. News
AllArticlesVideos
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
Business Wire·2 days ago
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
Business Wire·1 week ago
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Neurogene, Inc. stock?
Neurogene, Inc. (NGNE) has a market cap of $414M as of April 30, 2026.
What is the P/E ratio for Neurogene, Inc. stock?
The price to earnings (P/E) ratio for Neurogene, Inc. (NGNE) stock is 0 as of April 30, 2026.
Does Neurogene, Inc. stock pay dividends?
No, Neurogene, Inc. (NGNE) stock does not pay dividends to its shareholders as of April 30, 2026.
When is the next Neurogene, Inc. dividend payment date?
Neurogene, Inc. (NGNE) stock does not pay dividends to its shareholders.
What is the beta indicator for Neurogene, Inc.?
Neurogene, Inc. (NGNE) has a beta rating of 1.89. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.